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OSTEOGENIC CELLS (OSTEOBLASTS)
Osteoblasts arise from multipotent mesenchymal stem cells, and are responsible for the secretion of the organic components of the bone matrix, or collagen (type I) and proteoglycans, as well as for the synthesis of osteocalcin, osteopontin and proteinases. Their functions are also regulated by parathormone (PTH) and 1,25-dihydroxyvitamin D (1,25(OH) 2 D 3 ) [23] . The differentiation of osteoclasts is due to modification of osteoblasts through expression of RANKL that activates the development of osteoclasts, and to secretion of osteoprotegerin (OPG) that blocks the effect of RANKL [23] . The proliferation and maturation of osteoblasts is influenced by many other growth factors (IGF1, IGF2, TGF-β1, TGF-β2, BMP, FGF, VEGF and PDGF). Pro-inflammatory cytokines, such as IL-1 or TNF, play a role in the induction of osteogenic cells and increase RANKL expression, thus causing disorders of bone metabolism.
OSTEOCLASTS
Osteoclasts are 50 to 100 µm in diameter, and have prominent Golgi apparatus and eosinophilic cytoplasm that is rich in mitochondria, lysosomes and polyribosomes. Osteoclasts also have polarity. This is due to plications within the cell membrane in the form of microvilli located on the side of the bone tissue surface (a so-called ruffled border). The ruffled border plays an important part in bone resorption that is taking place in Howship's lacunae. Contact between osteoclasts and bone matrix is possible due to integrins αvβ3 present on their surface. Their occurrence and activity can be inhibited by the following factors: oestrogens, OPG, IL-4, IL-18, TGF-β, IFN-γ, FGF-2, calcitonin and bisphosphonates [21, 23] . On the contrary, IL-1, IL-6, IL-11, TNF, PGE 2 , M-CSF and vitamin D3 induce osteoclast formation through RANKL production stimulated by osteoblasts and bone marrow stromal cells [23, 27] . As a consequence of bone degradation, the local growth factors, i.e. TGF-β, FGF or BMP are released from the matrix to stimulate the maturation of the precursors of osteoblasts that produce osteoprotegerin (OPG), the main osteoclastogenesis inhibitor [17, 18, 23] .
OSTEOCLASTOGENESIS
The regulation of osteoclastogenesis, and, consequently, of bone resorption, is influenced by the following factors:
• generally acting hormones, • locally acting hormones, • the effects of cell-cell interactions (osteoblast/bone marrow stromal cell-precursor/osteoclast) [1] . It has been found that it is osteoblasts and bone marrow stromal cells, not osteoclasts, that have receptors for the hormones responsible for the stimulation of bone resorption. These are: 1,25 (OH) 2 D 3 and PTH.
Under the action of these hormones, such cells produce and release into the environment a number of factors acting in a paracrine or autocrine manner. Among these are the Macrophage Colony -Stimulating Factor (M-CSF), interleukins (IL-1, IL-6, IL-11) or prostaglandin E 2 (PGE 2 ).
The effects of cell-cell interactions (osteoblast/bone marrow stromal cell-precursor/osteoclast), in which relevant receptors and ligands are bound to cell membranes, are of great importance for the osteoclastogenesis and the activation of mature multinucleated osteoclasts. This system consists of three elements: a RANK receptor, osteoprotegerin and a ligand for the RANK receptor (RANKL) [1] .
RANKL/RANK/OPG PATHWAY
Proper osteoclast maturation and function are dependent on a pathway comprising osteoprotegerin (OPG), the Receptor Activator of Nuclear Factor -κ B (RANK) and its RANK ligand (RANKL -Receptor Activator of Nuclear Factor -κ B ligand) [4, 10, 25] . A fully active osteoclast is formed due to the activation of a cascade mechanism inside a maturing bone resorption cell, resulting from the binding of the Receptor Activator for Nuclear Factor κ B ligand (RANKL) with the Receptor Activator of Nuclear Factor κ B (RANK) on the surface of osteoclast precursor cells. This process involves osteoprotegerin (OPG), which is a protein from the tumour necrosis factor receptor family [8, 24] . The expression levels of RANKL (increase of resorption) and OPG (increase of bone formation) proteins can be influenced by a number of substances and cytokines (Table 1 ) [25] . 
OSTEOPROTEGERIN
Osteoprotegerin (OPG) is a protein that was first described in 1997. It was identified as a secreted molecule that inhibits the differentiation and activity of osteoclasts, i.e. as an osteoclastogenesis inhibitory factor [1, 4, 25] . OPG is a member of the tumour necrosis factor receptor (TNFR) superfamily and is synthesized predominantly by osteoblasts and many organs (lungs, liver, intestines, kidneys, stomach, skin, bones), as well as by periodontal tissues, gingival epithelium and gingival fibroblasts [5, 23] . Like RANKL, OPG is modulated by the inflammatory cytokines present in periodontitis [2] .
Osteoprotegerin is a dummy receptor that competitively binds to RANKL/OPGL [28] . This prevents osteoblasts and bone marrow stromal cells from contacting both the precursors and the mature multinucleated osteoclasts having a RANK receptor, and results in inhibition of osteoclastogenesis (Figure 1) . OPG expression is promoted by many factors, such as interleukins (IL-1α, IL-6, IL-11, IL-13, IL-18), growth factors (PDGF, TGF-β1), 17β-estradiol, OSM (oncostatin M) or mechanical loads exerted on bone [19] . In contrast, OPG inhibitors are: parathormone (PTH), PGE 2 , immunosuppressive drugs, glucocorticoids, vitamin D 3 and its derivatives [1, 2, 4, 19, 20, 22] .
RANK LIGAND (RANKL)
RANKL (Receptor Activator for Nuclear Factor κ B Ligand) belongs to the protein superfamily of tumour necrosis factors (TNF) and is a product of mature osteoblasts, along with their precursors, fibroblasts, chondrocytes, endothelium, bone marrow stromal cells, malignant cells or active T lymphocytes. It is a factor that activates formation of mature osteoclasts: their differentiation, fusion, function and survival. RANKL acts via the RANK receptor (Receptor Activator for Nuclear Factor κ B) present on the cell surfaces [1] . RANKL activates osteoclastogenesis by blocking apoptosis of osteoclasts, while binding to RANK which is present on the surface of resorption cells, or osteoclasts [6, 23] (Figure 2 ). RANKL gene expression is blocked by 17β-estradiol, and by IL-13 or TGF-β1 as well [19, 23] . Moreover, 1,25(OH) 2 D 3 , IL-1β, IL-6, IL-7, IL-11, IL-17, TNF, PTH, OSM, IFN-γ, PGE 2 vitamin D 3 , glycocorticosteroids and dexamethasone promote an increase in gene expression for RANKL in the presence of M-CSF [1, 19, 23, 25] .
RECEPTOR ACTIVATOR OF NUCLEAR FACTOR -Κ B (RANK)
RANK is a type I glycoprotein from the TNF receptor superfamily that is the receptor RANKL, or the most important cytokine that is responsible for the development and maturation of osteoclasts. It is a transmembrane protein that can be found in mature osteoclasts and their precursors, fibroblasts, T and B lymphocytes, chondrocytes, endothelial cells, dendritic cells, and in malignant cells as well [1, 2, 11, 13, 19, 23, 28] . Increased RANK expression is due to the activity of RANKL, IL-1, MIP-1α, VIP, oncostatin M (OSM), vitamin D 3 , TGF-β and IFN-γ, whereas the reduction of the number of RANK molecules on the surface of osteoclasts may be induced by IL-4 [1, 2, 4, 23, 26] .
RANKL AND OPG EXPRESSION IN PERIODONTAL DISEASE
Numerous studies showed that IL-1, IL-6 and TNF-α, as well as other inflammatory cytokines, are significant in Current Issues in Pharmacy and Medical Sciences periodontal disease due to the fact that they control RANKL and OPG expression [3, 25] . OPG and RANKL are regarded as the main bone metabolism regulators and are also considered to be crucial for the mechanism of periodontal destruction in periodontitis [3] .
Inflammatory cell infiltration in chronic periodontal disease leads to bone atrophy in periodontitis. This situation is reflected in increased RANKL and decreased OPG in the inflammatory granulation tissue adjacent to the atrophied bone. [3.25] . According to Nagasawa et al., RANKL expression is higher in deeper periodontal pockets, compared to the physiological gingival pockets [15, 16] . Liu et al. also confirmed that the RANKL level was higher in people with the advanced stage of periodontal disease, compared to those with moderate periodontitis or those who are healthy [4, 12, 15] .
RANKL mRNA expression was observed in inflammatory cells, mainly in lymphocytes and macrophages. Furthermore, the proliferating epithelium in the region of proinflammatory cells also exhibited increased expression of RANKL mRNA [2, 15] .
Using immunohistochemical methods, Crotti et al. compared RANKL and OPG expression in the inflammatory granulation tissue adjacent to the places of bone atrophy in periodontal patients with the parodontal tissues, and in patients without any symptoms of periodontal disease [2, 15] . Herein, the level of RANKL proteins was significantly higher in tissues with clinical parodontopathy, whereas the OPG level turned out to be clearly lowered [2, 15, 25] .
Mogi et al. measured RANKL and osteoprotegerin concentrations in Gingival Crevicular Fluid (GCF) in patients with periodontitis and in healthy ones. Increased RANKL and decreased OPG were obtained for the group with diagnosed periodontitis. Furthermore, the ratio of the concentration of RANKL to that of OPG in Gingival Crevicular Fluid was significantly higher in that group, compared to the ratio found for the group of healthy people [14, 15] .
The RANKL/OPG ratio can be seen as the main determinant of bone metabolism. In many situations, bone absorption is stimulated by both the increased RANKL level and the decreased OPG level which act as pro-resorptive signals [9] .
The mechanisms behind the bone resorption process in periodontal disease is still being investigated. Progress in medicine is extremely fast, and medical discoveries made ten years ago often become anachronisms. Still, a willingness is triggered amongst researchers to discover what has not been fully investigated yet. Amongst such targets are (for example) the regulation effect and mechanisms in other physiological and pathological situations of the organism.
Currently, sRANKL and OPG as inflammatory process markers, seem to have as yet limited practical applications due to the multitude of tissues that are sources of the proteins in question. However, the role of RANKL inhibitors as therapeutic agents for treatment of conditions involving bone mass loss, as for example postmenopausal osteoporosis, myeloma or breast carcinoma, is promising [9, 10] .
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